Renaissance Technologies LLC Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Renaissance Technologies LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.8% during the first quarter, Holdings Channel reports. The fund owned 2,152,528 shares of the biopharmaceutical company’s stock after selling 636,200 shares during the quarter. Gilead Sciences comprises 0.5% of Renaissance Technologies LLC’s portfolio, making the stock its 25th biggest holding. Renaissance Technologies LLC’s holdings in Gilead Sciences were worth $299,998,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on GILD shares. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Monday, July 6th. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $146.00 to $127.00 in a research report on Tuesday. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Finally, Daiwa Securities Group dropped their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $158.33.

Gilead Sciences Trading Down 1.2%

Shares of NASDAQ GILD opened at $129.31 on Friday. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm has a 50-day moving average of $129.55 and a 200 day moving average of $135.50. The stock has a market cap of $160.55 billion, a P/E ratio of 17.62 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the business earned $1.81 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 77,000 shares of company stock valued at $9,978,740. 0.30% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.